Anika beats Q3 revenue estimates, maintains guidance

Anika Therapeutics

05/11/2025 12:12

Overview

Anika Q3 revenue decreases 6% yr/yr to $27.8 mln, beating analyst expectations

Commercial Channel revenue up 22%, driven by Integrity and international OA growth

Company starts $15 mln share repurchase, reaffirming fiscal 2025 guidance

Outlook

Anika maintains 2025 Commercial Channel revenue guidance at $47 to $49.5 mln

Anika maintains 2025 OEM Channel revenue guidance at $62 to $65 mln

Company commences $15 mln share repurchase, expected by June 2026

Result Drivers

COMMERCIAL CHANNEL GROWTH - Revenue increased 22% driven by Integrity Implant System and international OA Pain Management

OEM CHANNEL DECLINE - Revenue decreased 20% due to lower U.S. pricing for Monovisc and Orthovisc

INTERNATIONAL SALES - International OA Pain Management saw double-digit growth, contributing to overall performance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$27.81 mln
$27.80 mln (2 Analysts)
Q3 Net Income
-$2.32 mln
Q3 Gross Profit
$15.58 mln
Q3 Income from Operations
-$3.23 mln
Q3 Pretax Profit
-$2.23 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Anika Therapeutics Inc is $15.50, about 37.9% above its November 4 closing price of $9.63

Press Release: ID:nGNX139ytB

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)